Healthcare
Live Price
Offline$38.86
+0.00% today
1Y Change
+4.51%
Window
Jun 27, 2025 → Jun 24, 2026
Coverage: 253 bars · Jun 27, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Orion Oyj (ORINY) is a Healthcare stock with a market cap of $9.67B and listed on OTC. The stock last traded around $38.86 and up 4.5% across the available one-year price window (Jun 27, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of +22.5%, EPS growth of -27.2%, a dividend yield of 2.5%. What stands out right now is revenue +22.5%, EPS -27.2%, free cash flow +6.2% with operating margin 34.1% and ROIC 35.4%. The dividend matters to the case here, with a current yield around 2.5%. Valuation sits in the middle of the pack at P/E 18.3 and price/sales 5.0. Overall, the current profile looks closer to a quality compounder than a generic broad-market placeholder. Stock Foundry combines ORINY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ORINY
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ORINY Max Drawdown
-25.57%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ORINY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.0B
-22.4% YoY
FY Net Income
$193.8M
-44.5% YoY
Free Cash Flow
$130.7M
-63.8% YoY
Revenue Growth
+22.5%
EPS Growth
-27.2%
Gross Margin
64.8%
Net Margin
27.1%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.5B | 1.2B | 1.3B | 1.0B |
| Gross Profit | 1.2B | 946M | 658M | 849M | 594M |
| Operating Income | 632M | 417M | 275M | 440M | 243M |
| EBITDA | 656M | 514M | 329M | 489M | 289M |
| Net Income | 481M | 330M | 217M | 350M | 194M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 161M | 206M | 107M | 333M | 217M |
| Total Assets | 2.0B | 1.6B | 1.4B | 1.5B | 1.1B |
| Total Liabilities | 725M | 624M | 549M | 596M | 366M |
| Shareholder Equity | 1.3B | 1.0B | 890M | 908M | 748M |
| Total Debt | 305M | 327M | 200M | 214M | 109M |
| Net Debt | 144M | 122M | 93M | -119M | -108M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
216M
-50.3% YoY
Capital Expenditures
85M
-16.3% YoY
Free Cash Flow
131M
-63.8% YoY
Key ratios
Gross Margin
64.8%
Operating Margin
34.1%
Net Margin
27.1%
ROE
48.7%
Debt / Equity
0.29x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.